Check Your Fridge: Dr Pepper Is Recalling More Than 19,000 Cans in 3 States

The FDA has reclassified a recall for Dr Pepper Zero Sugar as a Class II recall.
The 19,203 affected sodas were recalled due to incorrect labeling, as the beverages were found to contain the same amount of sugar as regular Dr Pepper.
Customers who have purchased the recalled sodas, which were sold across three states, can return to them to their place of purchase for a full refund.The United States Food and Drug Administration (FDA) has upgraded an important recall for Dr Pepper over critical mislabeling.
On May 23, the FDA and Dr Pepper issued an initial, voluntary recall for more than 19,000 cans of Dr Pepper Zero Sugar, which, as their name implies, were labeled as having no sugar, but were later found to contain the full amount of sugar included in classic Dr Pepper. This makes the beverages potentially dangerous for those who are sensitive to sugar, including people with diabetes.
On June 5, the FDA reclassified the recall as a Class II, which it describes as a "situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
As outlined in the FDA's notice, the recall includes 19,203 cans, which were packaged in 12- or 24-pack cases of 12-fluid-ounce cans. Affected items will have the product code XXXXRS05165, and each case comes with a 'Best By' date of February 16, 2026.
The cases were distributed in Florida, Georgia, and South Carolina. If you have already bought the recalled product, the FDA notes that you can return it to your place of purchase for a full refund.
Unfortunately for consumers, this isn't the only beverage currently affected by an FDA recall. Earlier in June, Coca-Cola issued a voluntary recall of its Topo Chico mineral water in five states due to concerns about potential Pseudomonas contamination, a bacteria that can be deadly to individuals with weakened immune systems.
The Topo Chico recall included five states, Arizona, Louisiana, Nevada, New Mexico, and Texas, where the product was distributed to 40 different Costco locations. Just like with the recalled Dr Pepper Zero Sugar, consumers can simply return the mineral water to their place of purchase for a refund.
Related: 20 Million Eggs Pulled from Shelves After CDC Traces Deadly Bacteria to California Facility
Although it may seem like there's been an increase in the number of food and drink recalls over the past year, this isn't quite the case — but the number of hospitalizations associated with recalls is up year-over-year.
As Food & Wine previously reported, while the combined number of recalls issued by the FDA and the United States Department of Agriculture (USDA) declined in 2023, the number of hospitalizations and deaths caused by recalled items more than doubled, totaling 487 hospitalizations and 19 deaths in 2024. If you've accidentally purchased or consumed a recalled item, it's critical to take the issue seriously and reach out to your medical provider as necessary.Product recalled: Dr Pepper Zero Sugar, packaged in 12- or 24-pack cases of 12-fluid-ounce cans
Reason for recall: Incorrectly labeled as sugar-free
Number of cans recalled: 19,203
Product code: XXXXRS05165
States affected: Florida, Georgia, and South CarolinaRead the original article on Food & Wine

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

BMO says lenacapavir approval for prevention a ‘major win' for Gilead

Although largely as expected by investors, BMO Capital says lenacapavir's approval for prevention, now known as Yeztugo, marks 'a major win for Gilead (GILD)' in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue Cautious Optimism for Gilead Sciences Amid Yeztugo's Market Challenges Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead Mizuho says Gilead Yeztugo label looks clean Gilead Sciences' Yeztugo Approval and Market Expansion Drive Buy Rating Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option

Forbes

2 hours ago

• Forbes

Technology Has A Role To Play As Research Adapts To New Constraints

Jiang Li, Ph.D., is the Founder and CEO of Vivalink, Inc. Hybrid and decentralized clinical trials (DCTs) have been gaining momentum in recent years. Following the pandemic, sponsors and regulators increasingly adopted remote-friendly designs, regulatory agencies encouraged their adoption and digital health companies developed tools to facilitate these trials.​ In 2023, the FDA issued draft guidance on DCTs that promoted the use of decentralized elements, such as remote data collection, telehealth visits and wearable sensors, to enhance trial flexibility, efficiency and inclusivity. This guidance was finalized in September 2024, solidifying the FDA's support for incorporating decentralized elements in clinical trials. Policy shifts threaten progress. That momentum is now under pressure. The National Institutes of Health (NIH) funds the bulk of medical research in the U.S. But a new federal policy would cap overhead reimbursement at 15%, reducing indirect cost support for many research centers and potentially reshaping how academic science is funded. Plus, the Department of Health and Human Services has begun cutting nearly 10,000 employees and plans to eliminate a total of 20,000 positions. The layoffs, part of a sweeping restructuring effort, have already impacted core health agencies like the NIH and FDA. As a result, trials have been paused, grants delayed and many research institutions, including major universities and academic medical centers, have reduced staff or scaled back operations. These shifts have posed major challenges for the implementation of DCTs in academic and early-stage research, where adoption was just beginning to gain traction. With fewer staff and less funding, institutions face greater barriers to adopting and managing the technologies essential to decentralized trial models. Yet regulatory support for DCTs, and the need for efficient and accessible trials, haven't gone away. Technology alone can't offset these setbacks, but it can help support ongoing research by reducing operational burden, enabling remote participation and helping sponsors manage studies with fewer resources. Prioritize interoperability. The increased application of DCTs has introduced a growing array of tools into how research is conducted, including wearables, remote monitoring devices, telehealth platforms, mobile apps and dashboards. But as academic institutions and research centers face staffing cuts and constrained budgets, managing a patchwork of disconnected systems is increasingly unsustainable. This environment heightens the need to prioritize interoperability. Even before these changes, sponsors were leaning toward solutions that integrate easily into their existing workflows. Now, they're looking for platforms that reduce the operational burden on already stretched teams. Interoperability should be a core design consideration. Solutions that connect with EHRs, lab systems, participant-reported outcomes and sponsor dashboards can reduce friction, cut down on manual processes and allow research teams to focus on science instead of system management. Equally important are ready-to-use mobile apps and connected devices that require minimal setup or IT support. Planning for integration early, both across systems and devices, can help trials run more efficiently as organizations adapt to doing more with less. Deliver measurable impact. With tighter budgets and increased scrutiny, sponsors need to justify every dollar. That means technology must deliver clear and measurable results, whether by accelerating recruitment, improving retention, reducing site visits or producing more complete datasets. Flexibility is just as important. As trials evolve, sponsors need platforms that can adapt, such as being able to adjust mid-study, support multiple arms or accommodate late-stage protocol changes. Tools that can be configured on the fly or deployed across different trial designs help teams stay responsive when timelines shift or priorities change. Real-time monitoring and continuous data collection are shifting how sponsors track progress during a trial. These technologies often surface early insights and preliminary findings faster than traditional timelines would. As a result, teams now have an opportunity to adjust mid-study, including changes to the study design, resource allocation or cohort size. A recent study highlighted this need for adaptability, pointing to modular digital platforms as a way for sponsors to retain control when trial activities shift. But it also made clear that technology alone isn't enough. As these platforms evolve, clinical and technical teams will need to work together to build solutions that meet the needs of everyone involved, from investigators and sponsors to participants. Technology providers that offer both measurable impact and flexibility, without locking sponsors into rigid ecosystems, are better positioned to support research teams under pressure. Support what remains. Recent funding cuts are disrupting the infrastructure supporting early-stage and academic research, from lab space and shared equipment to staff and resources. While technology can't reverse these cuts, it can support the trials that continue and help sponsors maintain critical metrics like participant adherence. Studies have shown that technology solutions like remote monitoring and digital platforms can increase patient adherence. For example, a recent study using electronic diaries resulted in compliance rates of up to 94%, compared to just 11% with paper diaries. Another study found that remote patient monitoring has been proven to improve adherence to medications and lifestyle changes. Platforms that can track adherence in real time, send automated reminders and flag protocol deviations give research teams the visibility they need to act quickly. These systems can alert teams when a participant's device isn't sending data as expected, track whether devices are being used correctly and help staff identify participants who may need follow-up. With fewer team members and more limited oversight, access to this information is important. As research institutions shift from growth to preservation, technology is playing a more functional role. Technology can't replace the research that's been paused or the teams that have been downsized, but it can help keep ongoing trials on track. That includes maintaining data quality, flagging issues early and helping teams follow up when participants miss visits or fall behind. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Politico

3 hours ago

• Politico

RFK Jr.'s past claims shadow vaccine panel agenda

Presented by With help from Amanda Chu and Danny Nguyen Driving the Day ACIP AGENDA CHANGE — The agenda for next week's Advisory Committee on Immunization Practices meeting includes some notable differences from the notice posted in the Federal Register earlier this month, Sophie reports with POLITICO's Lauren Gardner. Most notably, the panel will hold two separate votes for the flu shot: one on influenza vaccines and another on influenza vaccines that contain thimerosal. In 2014, before he became health secretary, Robert F. Kennedy Jr. wrote a book in which he alleges the vaccine preservative thimerosal likely caused autism and should be banned — a claim that health agencies now under his control have said is unfounded. Thimerosal continues to be used as a preservative in multidose vaccine vials to inhibit germ growth. But its use in FDA-licensed flu vaccines has declined over the past 25 years as manufacturers reformulated their products and shifted to single-use vials. Most of those contain little or no thimerosal, according to the CDC. The meeting marks the first for Kennedy's revamped ACIP roster — following the firing of the previous 17 members — which includes several vaccine skeptics. No Covid vote: The agenda does not include a vote on Covid-19 vaccines, despite the Federal Register notice saying a vote is planned. Last month, Kennedy updated the CDC's Covid recommendations without a vote from the panel, breaking from tradition. Kennedy removed the recommendation that pregnant women get the shot, and the CDC changed the recommendation for healthy children to 'shared clinical decision making' — meaning children 'may' get vaccinated if their doctors and parents want them to. The HPV vaccine and meningococcal vaccine were also slated for a vote according to the meeting's Federal Register notice but aren't included in the draft agenda. Cut short? The agenda for the advisory committee's meeting includes only two days, June 25 and 26, but the initial Federal Register notice said the panel would also meet on June 27. A spokesperson for HHS did not comment on the thimerosal vote or why the agenda for the 27th wasn't included. WELCOME TO FRIDAY PULSE. For more on what next week's ACIP agenda holds, keep reading. Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @Kelhoops and @sophie_gardnerj. Vaccines 'THEY CROSSED THE LINE' — Dr. Fiona Havers, a CDC scientist who collected and compiled data on Covid-19 and respiratory syncytial virus before stepping down this week, told POLITICO that HHS Secretary Robert F. Kennedy Jr.'s overhaul of the agency's outside panel of vaccine experts was her final straw. 'I knew at that point that they had crossed the line,' Havers said. 'As a physician and a scientist, and for my own personal integrity, I did not feel like I could stay and legitimize this process.' The Advisory Committee on Immunization Practices votes on vaccine recommendations, playing an integral role in developing childhood and adult vaccine schedules. Last week, Kennedy fired the entire panel and replaced them with members he hand-selected. The first meeting of the new members is scheduled for next week. Havers often presented data to the panel to inform its decisions. I spoke with Havers about her decision to resign and what she will be watching for at next month's meeting. Here's our conversation, edited for length and clarity. What made you resign? [It was a] culmination over the last one to two months of RFK Jr. trashing the vaccine policy recommendation process at CDC. This has been building for a while. Several events have really undermined the vaccine policy process. One was in late May, when FDA officials released this regulatory framework suggesting that only those 65 years older and people with underlying medical conditions should receive [updated] Covid-19 vaccines. Then the following week, the HHS secretary announced on X that the Covid vaccines for healthy children and healthy pregnant women had been removed from the CDC recommended vaccine immunization schedule … Basically, RFK Jr. was making CDC vaccine policy on X without involving CDC. And that was pretty shocking, because there's a very rigorous process in place. Then last week, when they announced the firing of all 17 ACIP members, I knew I was done. Can you share any thoughts on Kennedy's replacement picks? These people are, for the most part — with very few possible exceptions — not the people that should be sitting on ACIP. What will you be watching at the meeting next week? If CDC is presenting the data … the data coming out of CDC is still solid. As of now, I can speak to the fact that the COVID-NET and RSV-NET data is high-quality evidence and can be believed. How those data get used to make vaccine policy decisions is really what's in question right now. Seeing the kind of questions that they ask and what they say may give some clue as to how they may vote in the future. I am very concerned that there's going to be a restricting of access to vaccines for people that otherwise should be getting them, and we'll get some sense of if that's actually going to happen. HHS response: HHS spokesperson Andrew Nixon told POLITICO that HHS is 'committed to following the gold standard of scientific integrity,' and 'vaccine policy decisions will be based on objective data, transparent analysis and evidence — not conflicts of interest or industry influence.' AROUND THE AGENCIES GAIN-OF-FUNCTION CUTS — The National Institutes of Health is cutting and suspending funding for gain-of-function research, a move that will impact biomedical projects conducted globally, Danny reports. The NIH's directive, released Wednesday, will immediately terminate funding and other support for gain-of-function research conducted by 'foreign entities in countries of concern or foreign countries where there is no adequate oversight.' The order didn't explicitly name the targeted groups and countries. The NIH did not respond to a request for comment. The agency will also suspend funding and additional support for all other gain-of-function research and has asked researchers who receive NIH funds to identify other projects not yet identified by the agency that fit the category by June 30. Gain-of-function research involves genetically altering biological organisms to enhance transmission or other functions, which can help scientists identify therapeutic targets. Key context: The move comes months after the Trump administration marked gain-of-function research as dangerous. Earlier this year, the administration said the Covid pandemic was caused by a lab leak from gain-of-function research at a virology research institute in the Chinese city of Wuhan, where the virus first appeared. Many scientists, however, believe the disease was caused by natural spillover from an animal to a human. The Trump administration's theory, memorialized in a glossy website unveiled in April, prompted President Donald Trump to issue an executive order last month to eliminate federal funding for gain-of-function research in countries such as China, which Trump has criticized for inadequate research oversight. The NIH's latest missive delivers on this executive order. In other research news: The FDA announced Wednesday it would immediately review new clinical trials that 'involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into U.S. patients — sometimes without their knowledge or consent.' The order, endorsed by the NIH, is another swipe at foreign research — particularly studies performed in China, which the administration has characterized as poorly regulated. Industry Intel BURR'S LOBBYING GIG — The Biotechnology Innovation Organization, the world's largest biotech organization, has tapped former Republican Sen. Richard Burr (R-N.C.) to lobby on issues related to drug pricing and supply chains, Medicare and Medicaid and reauthorization of the Pandemic and All-Hazards Preparedness Act, Amanda reports. Now health policy chair at law firm DLA Piper, Burr was the top Republican on the Senate Health, Education, Labor and Pensions Committee and was a champion of reforming the FDA. Jamie Gregorian, a former senior policy adviser at the FDA and assistant to Burr in the Senate, will also represent BIO at DLA Piper, according to the law firm's disclosure submitted today. The outside hire from BIO marks the third for the group this year and comes as the biotech industry faces a steep drop in investor funding amid President Donald Trump's cuts to regulatory agencies. Earlier this week, BIO hired former Trump White House adviser Matt Mowers and Trump's campaign deputy director Bill Killion, who both now work at Valcour, a Washington-based lobbying firm. WHAT WE'RE READING POLITICO's Jordain Carney and Robert King report that Senate Republican leaders are seeking ways to tamp down moderates' worries about the megabill's possible impact on rural hospitals. The New York Times' Roni Caryn Rabin reports on the Trump administration's travel restrictions impacting medical residents.